FDA Launches New Patient Engagement Collaborative, Call for Nominations

IACP Members: Encourage Your Patients to Get Involved – Make Their Voices Heard on FDA’s New Site – Why Access is NEEDED to Compounded Medications!

The Food & Drug Administration (FDA) is launching a Patient Engagement Collaborative https://blogs.fda.gov/fdavoice/index.php/author/mcooper/ and has issued a Call for Nominations. http://bit.ly/2zWVqZk

According to the Agency, “FDA is committed to collaborating with patients, caregivers, and advocates, as well as incorporating the various perspectives from these groups into the FDA’s regulatory decision-making processes. And we know that patients and other stakeholders agree with the agency’s commitment to improving and increasing patient involvement in FDA matters. In fact, members of the patient and stakeholder communities commented in public feedback on Section 1137, Patient Participation in Medical Product Discussions, of the Food and Drug Administration Safety and Innovation Act (FDASIA). Stakeholders recommended that the FDA create an outside group to provide input on patient engagement across the agency. We are pleased to announce that in response to that feedback and to accelerate the FDA’s efforts in this area, today the FDA published a request for nominations to join the FDA’s Patient Engagement Collaborative (PEC).”

Nominations received by 11:59 p.m. Eastern Time on or before January 29, 2018, will be given first consideration for membership on the PEC. Nominations received after the submission deadline will be retained for future consideration. Click here for FDA nominations form. http://bit.ly/2zWVqZk